EU nod for Merck’s MS therapy Mavenclad

25th August 2017 Uncategorised 0

Merck’s Mavenclad has bagged approval in the European Union, Norway, Liechtenstein and Iceland to treat highly active relapsing multiple sclerosis.

More: EU nod for Merck’s MS therapy Mavenclad
Source: News